DEVELOPING INNOVATIVE DRUG CANDIDATES TO IMPROVE THE LIVES OF CANCER PATIENTS

Our lead programs, TTI-621 and TTI-622, are SIRPαFc decoy receptors designed to block the CD47 “do not eat” signal and activate both the innate and adaptive immune systems. Below please find a list of our current clinical trials.